磷酸化雄激素受體抗體 返回列表頁(yè)

英文名稱 phospho-Androgen Receptor (Ser213)
中文名稱 磷酸化雄激素受體抗體
別    名 Androgen Receptor (phospho S213); Androgen Receptor (Phospho-Ser213); Androgen Receptor (phospho Ser213); p-Androgen Receptor (Ser213); ANDR_HUMAN; HYSP1; AIS; Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease); AR; DHTR; Dihydro Testosterone Receptor; Dihydrotestosterone receptor; HUMARA; Nuclear receptor subfamily 3 group C member 4; SBMA; SMAX1; Spinal and bulbar muscular atrophy; TFM.
磷酸化雄激素受體抗體
   
說(shuō) 明 書(shū) 0.1ml  
產(chǎn)品類型 磷酸化抗體 
研究領(lǐng)域 腫瘤  免疫學(xué)  
抗體來(lái)源 Rabbit
克隆類型 Polyclonal
交叉反應(yīng) Human, 
產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 101kDa
細(xì)胞定位 細(xì)胞核 細(xì)胞漿 
性    狀 Lyophilized or Liquid
濃    度 1mg/1ml
免 疫 原 KLH conjugated Synthesised phosphopeptide derived from human Androgen Receptor around the phosphorylation site of Ser213 [ER(p-S)GA]
亞    型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

產(chǎn)品介紹 background:
The androgen receptor gene is more than 90 kb long and codes for a protein that has 3 major functional domains: the N-terminal domain, DNA-binding domain, and androgen-binding domain. The protein functions as a steroid-hormone activated transcription factor. Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. This gene contains 2 polymorphic trinucleotide repeat segments that encode polyglutamine and polyglycine tracts in the N-terminal transactivation domain of its protein. Expansion of the polyglutamine tract causes spinal bulbar muscular atrophy (Kennedy disease). Mutations in this gene are also associated with complete androgen insensitivity (CAIS). Two alternatively spliced variants encoding distinct isoforms have been described. [provided by RefSeq, Jul 2008]

Function:
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3. [ENZYME REGULATION] AIM-100 (4-amino-5,6-biaryl-furo[2,3-d]pyrimidine) suppresses TNK2-mediated phosphorylation at Tyr-267. Inhibits the binding of the Tyr-267 phosphorylated form to androgen-responsive enhancers (AREs) and its transcriptional activity.

Subunit:
Binds DNA as a homodimer. Part of a ternary complex containing AR, EFCAB6/DJBP and PARK7. Interacts with HIPK3 and NR0B2 in the presence of androgen. The ligand binding domain interacts with KAT7/HBO1 in the presence of dihydrotestosterone. Interacts with EFCAB6/DJBP, PELP1, PQBP1, RANBP9, RBAK, SPDEF, SRA1, TGFB1I1, ZNF318 and RREB1. Interacts with ZMIZ1/ZIMP10 and ZMIZ2/ZMIP7 which both enhance its transactivation activity. Interacts with SLC30A9 and RAD54L2/ARIP4. Interacts via the ligand-binding domain with LXXLL and FXXLF motifs from NCOA1, NCOA2, NCOA3, NCOA4 and MAGEA11. The AR N-terminal poly-Gln region binds Ran resulting in enhancement of AR-mediated transactivation. Ran-binding decreases as the poly-Gln length increases. Interacts with HIP1 (via coiled coil domain). Interacts (via ligand-binding domain) with TRIM68. Interacts with TNK2. Interacts with USP26. Interacts with RNF6. Interacts (regulated by RNF6 probably through polyubiquitination) with RNF14; regulates AR transcriptional activity. Interacts with PRMT2 and TRIM24. Interacts with GNB2L1/RACK1. Interacts with RANBP10; this interaction enhances dihydrotestosterone-induced AR transcriptional activity. Interacts with PRPF6 in a hormone-independent way; this interaction enhances dihydrotestosterone-induced AR transcriptional activity. Interacts with STK4/MST1. Interacts with ZIPK/DAPK3. Interacts with LPXN. Interacts with MAK. Part of a complex containing AR, MAK and NCOA3.

Subcellular Location:
Nucleus. Cytoplasm. Note=Predominantly cytoplasmic in unligated form but translocates to the nucleus upon ligand-binding. Can also translocate to the nucleus in unligated form in the presence of GNB2L1.

Tissue Specificity:
Isoform 2 is mainly expressed in heart and skeletal muscle.

Post-translational modifications:
Sumoylated on Lys-386 (major) and Lys-520. Ubiquitinated. Deubiquitinated by USP26. 'Lys-6' and 'Lys-27'-linked polyubiquitination by RNF6 modulates AR transcriptional activity and specificity.
Phosphorylated in prostate cancer cells in response to several growth factors including EGF. Phosphorylation is induced by c-Src kinase (CSK). Tyr-534 is one of the major phosphorylation sites and an increase in phosphorylation and Src kinase activity is associated with prostate cancer progression. Phosphorylation by TNK2 enhances the DNA-binding and transcriptional activity and may be responsible for androgen-independent progression of prostate cancer. Phosphorylation at Ser-81 by CDK9 regulates AR promoter selectivity and cell growth. Phosphorylation by PAK6 leads to AR-mediated transcription inhibition.
Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.

DISEASE:
Defects in AR are the cause of androgen insensitivity syndrome (AIS) [MIM:300068]; previously known as testicular feminization syndrome (TFM). AIS is an X-linked recessive form of pseudohermaphroditism due end-organ resistance to androgen. Affected males have female external genitalia, female breast development, blind vagina, absent uterus and female adnexa, and abdominal or inguinal testes, despite a normal 46,XY karyotype.
Defects in AR are the cause of spinal and bulbar muscular atrophy X-linked type 1 (SMAX1) [MIM:313200]; also known as Kennedy disease. SMAX1 is an X-linked recessive form of spinal muscular atrophy. Spinal muscular atrophy refers to a group of neuromuscular disorders characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. SMAX1 occurs only in men. Age at onset is usually in the third to fifth decade of life, but earlier involvement has been reported. It is characterized by slowly progressive limb and bulbar muscle weakness with fasciculations, muscle atrophy, and gynecomastia. The disorder is clinically similar to classic forms of autosomal spinal muscular atrophy. Note=Caused by trinucleotide CAG repeat expansion. In SMAX1 patients the number of Gln ranges from 38 to 62. Longer expansions result in earlier onset and more severe clinical manifestations of the disease.
Note=Defects in AR may play a role in metastatic prostate cancer. The mutated receptor stimulates prostate growth and metastases development despite of androgen ablation. This treatment can reduce primary and metastatic lesions probably by inducing apoptosis of tumor cells when they express the wild-type receptor.
Defects in AR are the cause of androgen insensitivity syndrome partial (PAIS) [MIM:312300]; also known as Reifenstein syndrome. PAIS is characterized by hypospadias, hypogonadism, gynecomastia, genital ambiguity, normal XY karyotype, and a pedigree pattern consistent with X-linked recessive inheritance. Some patients present azoospermia or severe oligospermia without other clinical manifestations.

Similarity:
Belongs to the nuclear hormone receptor family. NR3 subfamily.
Contains 1 nuclear receptor DNA-binding domain.

Database links:

Entrez Gene: 367 Human

Entrez Gene: 11835 Mouse

Entrez Gene: 24208 Rat

Omim: 313700 Human

SwissProt: P10275 Human

SwissProt: P19091 Mouse

SwissProt: P15207 Rat

Unigene: 496240 Human

Unigene: 39005 Mouse

Unigene: 394224 Mouse

Unigene: 439657 Mouse

Unigene: 9813 Rat
xy-13788R C19orf5219號(hào)染色體開(kāi)放閱讀框52抗體
xy-13789R C19orf5519號(hào)染色體開(kāi)放閱讀框55抗體
xy-13790R C19orf5619號(hào)染色體開(kāi)放閱讀框56抗體
xy-13791R C19orf5719號(hào)染色體開(kāi)放閱讀框57抗體
xy-13792R C19orf6119號(hào)染色體開(kāi)放閱讀框61抗體
xy-13798R C19orf7719號(hào)染色體開(kāi)放閱讀框77抗體
xy-13800R C1D核DNA結(jié)合蛋白C1D抗體
xy-13757R C1orf1581號(hào)染色體開(kāi)放閱讀框58抗體
xy-13758R C21orf6621號(hào)染色體開(kāi)放閱讀框66抗體
xy-13759R CDC42EP3CDC42效應(yīng)蛋白3抗體
xy-15268R C7orf 437號(hào)染色體開(kāi)放閱讀框43抗體
xy-10351R phospho-c-ABL (Tyr115)磷酸化非受體酪氨酸激酶c-Abl抗體
xy-10356R phospho-c-Abl (Thr754 + Thr735) 磷酸化非受體酪氨酸激酶c-Abl抗體
xy-10355R phospho-c-ABL (Tyr245)磷酸化非受體酪氨酸激酶c-Abl抗體
xy-10354R phospho-c-ABL(Thr413) 磷酸化非受體酪氨酸激酶c-Abl抗體
xy-10353R phospho-c-ABL(Tyr204)磷酸化非受體酪氨酸激酶c-Abl抗體
xy-10352R phospho-c-ABL (Thr754)磷酸化非受體酪氨酸激酶c-Abl抗體
xy-10309R Cenexin1精子尾部結(jié)構(gòu)蛋白抗體
xy-15198R C5orf19 5號(hào)染色體開(kāi)放閱讀框19抗體
xy-15313R C9orf1399號(hào)染色體開(kāi)放閱讀框139抗體
xy-15314R C9orf1409號(hào)染色體開(kāi)放閱讀框140抗體
xy-15315R C9orf1429號(hào)染色體開(kāi)放閱讀框142抗體